Tyra Biosciences (NASDAQ:TYRA) Trading Up 4.1%

Tyra Biosciences, Inc. (NASDAQ:TYRA)’s share price rose 4.1% during mid-day trading on Thursday . The stock traded as high as $21.13 and last traded at $20.92. Approximately 9,225 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 142,366 shares. The stock had previously closed at $20.10.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on TYRA shares. Wedbush restated an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a report on Wednesday, July 3rd. Oppenheimer reissued an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, July 3rd. Finally, HC Wainwright restated a “buy” rating and set a $23.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, July 3rd.

Tyra Biosciences Price Performance

The company’s 50-day simple moving average is $18.02 and its 200-day simple moving average is $16.99.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Thursday, May 9th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.11. Equities research analysts forecast that Tyra Biosciences, Inc. will post -1.71 EPS for the current fiscal year.

Insider Buying and Selling at Tyra Biosciences

In other news, COO Daniel Bensen sold 3,502 shares of Tyra Biosciences stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $20.00, for a total transaction of $70,040.00. Following the sale, the chief operating officer now directly owns 427,981 shares of the company’s stock, valued at $8,559,620. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 15.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Tyra Biosciences

Hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. increased its stake in shares of Tyra Biosciences by 43.9% in the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after buying an additional 3,180,155 shares during the last quarter. Kynam Capital Management LP grew its holdings in Tyra Biosciences by 51.4% during the 1st quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after acquiring an additional 175,000 shares in the last quarter. BVF Inc. IL grew its holdings in Tyra Biosciences by 70.1% during the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after acquiring an additional 1,921,599 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Tyra Biosciences by 18.6% in the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after purchasing an additional 140,833 shares during the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new stake in shares of Tyra Biosciences in the 1st quarter valued at about $977,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.